is an acceptable method of treatment for DTC patients with DM. It is unclear whether the sites of metastasis have any effect on the outcome or whether any treatment other than RI therapy is effective in improving the prognosis. In this study, we investigated the outcome of FTC patients with DM and attempted to identify prognostic factors.
materials and methods
Between 1989 and 2010, 13,264 thyroid carcinoma patients underwent initial surgical treatment at our institution, and the histological diagnosis in 645 (4.9%) of them was FTC. All of the surgical specimens were histologically reviewed by one of co-authors (KK) and the diagnoses were reconfirmed. The histological diagnosis and classification of FTCs were based on the most recent WHO classification system [8] . The presence of capsular and/or vascular invasion and the absence of nuclear features of papillary thyroid carcinoma defined cumulative cause-specific survival (CSS) rate from the time DM was first diagnosed was calculated by the Kaplan-Meier method. A univariate analysis was conducted in relation to CSS by the Kaplan-Meier method for several factors. The candidate predictors in the univariate analysis were gender, age at the time of DM diagnosis, site of DM, primary tumor size, invasiveness, number of organs to which DM had occurred when first detected, RI avidity, and treatment (RI therapy and surgical resection). Differences between groups were analyzed for significance by the log-rank test. The multivariate analysis was performed by using the Cox proportional hazards model. Significant factors were showed with the hazard ratio of each category, and p values <0.05 were regarded as statistically significant.
pathological diagnosis of FTC. The follicular variant of PTC was strictly excluded on the basis of nuclear feature of PTC. The FTCs were classified according to the extent of invasion by the tumor into widely invasive FTCs and minimally invasive FTCs. The widely invasive FTCs were characterized by widespread infiltration into blood vessels and/or adjacent thyroid tissue and were often incompletely encapsulated, whereas the minimally invasive FTCs were completely encapsulated tumors that had infiltrated the vessels located within or immediately outside the capsule and/or penetrated the full thickness of the capsule. After excluding the 62 patients with concomitant PTC, the 20 patients who had previously undergone thyroid surgery, the 5 patients with clear cell carcinoma and the 73 patients with oxyphilic cell carcinoma, the 485 remaining patients had ordinary FTC. As of a median follow-up time of 90 months, 106 (21.9%) of the 485 patients with ordinary FTC had been diagnosed with DM, and they were the subjects of this study. The clinical and pathological data are summarized in Table 1 . The subjects consisted of 70 females and 36 males, and their median age at the time of the initial surgery was 62 years (range: 10 to 84 years). The median follow-up period after the initial surgery was 66 months, and the median follow-up period after detection of DM was 50 months. The standard initial surgical procedure that has been used in our institution to treat patients with a follicular tumor is lobectomy. Whenever a patient has a concomitant benign thyroid disease i.e., Graves' disease or a nodular goiter of the opposite lobe, or has DM, total thyroidectomy is performed.
All of the subjects of this study were followed up in the outpatient clinic of our hospital. Whenever a gradual increase in postoperative serum thyroglobulin level was observed, a chest CT scan and bone scintigraphy and/or FDG-PET CT were performed. When these examinations resulted in the detection of metastasis in an M0 patient who had undergone hemithyroidectomy alone at the initial surgery, completion total thyroidectomy and RI therapy were recommended. Total thyroidectomy as the initial surgical procedure followed by RI therapy was recommended to all M1 patients. EBRT is indicated for patients with bone metastasis or brain metastasis. Especially for patients with pain from bone metastasis, we have usually recommended external beam radiation therapy (EBRT).
The data were analyzed with a statistical software program (JMP 8.0, SAS Institute, Inc., Cary, NC). The The protocol of this study was reviewed and approved by the Institutional Review Board, and the study was performed in accordance with the Declaration of Helsinki.
results

Patients' characteristics
In 65 (61%) of 106 patients DMs were present at the time of the initial surgery, and in the other 41 (39%) distant metastases were detected during the follow-up period (M2). Patients diagnosed with distant metastases less than 1 year after the initial surgery were classified as M1 patients, and patients diagnosed with distant metastases 1 year or more after the initial surgery were classified as M2 patients. The initial DM in the M2 patients was detected at a median interval of 66 months after initial surgery, and the intervals ranged from 24 to 189 months. The median age of the subjects when DM was first diagnosed was 62 years (range: 10 to 84 years). The initial surgery was total thyroidectomy in 56 patients and less than total thyroidectomy in the other 50 patients. In 22 patients, completion total thyroidectomy was performed after a histological diagnosis of FTC was made, and the other 28 patients underwent completion total thyroidectomy after the DM was detected. The DM sites detected first were bone alone in 39 patients (36.8%), lung alone in 49 patients (46.2%), lung and bone in 13 patients (12.3%), and other sites or combinations of sites in 5 patients (4.7%) (brain 2, lung and liver 1, lung bone and liver 1, mediastinum 1). The final DM sites were bone alone in 33 patients (31.1%), lung alone in 36 patients (34%), lung and bone in 28 patients (26.4%) and other sites or combinations of sites in 9 patients (8.5%) (brain 2, lung and brain 1, lung, bone and liver 1, lung, liver and brain 1, lung bone and brain 3, mediastinum 1) in 9 (8.5%). The relationships between the organs in which DM was detected first and the organs in which DM was detected as of the most recent follow-up examination are shown in Table 2 . Sixty four patients (61%) had lung metastasis at the time DM was first diagnosed and 49 of them had lung metastasis alone as of the most recent follow-up examination, whereas DM was subsequently detected in other organs in the other 13 patients. In 53 patients (50%) bone metastasis was detected when DM was first diagnosed, and in 33 of them bone metastasis alone was detected as of the most recent follow-up examination, whereas DM in another organ was subsequently detected in 6 patients.
The metastatic lesions were treated by RI therapy (80 patients), by surgical resection (36 patients), and by EBRT (27 patients). RI therapy was performed in 42 of the 65 patients with bone metastasis (11 of them underwent RI therapy alone, 17 received RI therapy and surgical treatment, 10 received RI therapy and EBRT, and 4 received RI therapy, surgical treatment and EBRT). Because the patients or the family did not hope additional therapy, 13 patients with bone metastasis did not receive any form of treatment for their DM. On the other hand, RI therapy was used to treat 44 of the 70 patients with lung metastasis and, RI ablation or RI examination alone was performed in the other 26 patients because their lesions did not take up RI. In 2 patients, EBRT was performed for their brain metastases and in 25 patients EBRT was performed for their bone metastases (22 patients for the spine, 3 patients for the pelvis).
Prognostic factor analysis
Twenty two patients (20.9%) died of their disease. The CSS rates at 5, 10, and 15 years after detection of DM were 82.2%, 63.8%, and 23.9%, respectively (Fig. 1) . The univariate analyses and multivariate analysis in regard to CSS identified age when DM was first diagnosed and primary thyroid tumor size as significant factors ( Fig. 2A, 2C , Table 3 ). Number of organs involved by distant metastasis when distant metastasis was first detected was significant factor in the univariate analysis, but not significant in the multivariate analysis. RI therapy and RI avidity were not significantly related to CSS either in the group of patients with lung metastasis or in the group of patients with bone metasta- DM and died of DM. RI therapy is the only available systemic modality of treatment for patients with DM, and for this reason has been repeatedly administered, even when it is not clearly effective. As we reported previously [7] , age was the most important factor related to DM-free survival of FTC patients and young FTC patients had a significantly lower risk of developing DM than old FTC patients. There were 13 patients (12.4%) under 45 years old in our present study. While only 2 of these 13 patients achieved a complete remission in response to RI therapy, the other 11 patients had stable disease without disease progression. In the present study we also showed that age was a strong prognostic factor in patients with DM. Because a high proportion of our subjects were elderly, we could not show RI therapy had a significant effect on the outcome of the patients with lung metastasis in our study. Elderly FTC patients are at higher risk of developing DM than younger patients, and elderly patients with DM have a poorer prognosis than younger patients. A significant relationship has been reported between age and iodine avidity in DTC [9] . Dedifferentiation of thyroid cancer may be related to poorer outcome and iodine avidity is thought to be one of the indicators of thyroid tumor differentiation. Several papers have reported finding a significant relationship between iodine avidity and the outcome of DTC patients with DM [10, 11, 12, 13] . But we could not show iodine avidity was not related to age sis. We could not show surgical treatment for patients with bone metastasis have an impact on the outcome. No patients with bone metastasis achieved a complete remission in response to RI, surgery, and/or EBRT.
Complete remission in response to RI therapy alone was observed in only 2 patients, a 10-year-old female and a 24 years-old-female, both of whom had lung metastasis. Comparison of the cumulative survival rate among patients with metastatic organs when distant metastasis was first detected was shown in Fig. 2D . There was no significant difference between patients with lung metastasis alone and patients with bone metastasis alone (p=0.878). But there was significant difference between patients with lung metastasis alone and patients with other single organ or multiple organs (p=0.0011), and between patients with bone metastasis alone and patients with other single organ or multiple organs (p=0.0084). The difference in outcome between the patients with bone metastasis and the patients with lung metastasis in our study was not significant.
discussion
DM is the most important prognostic factor for patients with differentiated thyroid cancer. Of our 485 FTC patients, a total of 25 patients died, 22 of their thyroid carcinoma and 3 of other causes. Of the 22 patients who died of thyroid carcinoma, all patients had tasis [19, 20] , but the difference in outcome between the FTC patients with bone metastasis and then FTC patients with lung metastasis in our study was not significant. Some recent studies have also shown that patients with both lung metastases and bone metastases have similar survival rates as those with bone metastases alone [16, 19] . Median age at the diagnosis of DM in patients with lung alone and patients with bone alone were both 59, and this might be why no significant difference was observed between the outcomes of these patients.
Chemotherapy has been believed ineffective for FTC and in our series, no patients was treated by chemotherapy. However, Besic et al. [20] recently reported neoadjuvant chemotherapy was effective for patients with advanced FTC before surgery. A multimodal therapeutic strategy that includes treatment with chemotherapy and/or a tyrosine-kinase inhibitor [21] should be prescribed to further improve the overall survival of FTC patients with DM, especially of patients with unfavorable prognostic factors.
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The authors declare that no competing financial interests exist. or outcome. RI avidity was exhibited by the lesions of 28 (65.1%) of the 43 patients aged 60 years of age or older in our study who underwent RI therapy or RI ablation and by the lesions of 29 (76.3%) of the 38 patients under than 60 of age who underwent RI therapy or RI ablation, but the difference was not significant.
On the other hand, surgical treatment and EBRT as well as RI therapy are other options for the treatment of FTC patients with bone metastasis. The role of surgery is debatable. Surgical treatment of bone metastases has been shown to be effective in FTC patients [14, 15] but, neither our study nor a study conducted by others has shown that surgical treatment improved the outcome of FTC patients with bone metastasis [16] . Surgical treatment of bone metastasis is usually performed in the expectation of relieving pain and preventing paralysis. Complete resection of bone metastasis is thought to be associated with better overall survival and can be curative [10, 14, 16] . The prognosis may also improve if bone metastasis is detected at its early stage [15, 16] . A recent study showed an excellent response of bone metastasis detected only by 131I scanning to RI therapy [17] . In contrast, there are no effective therapies for patients with poorly disseminated carcinomas that progress despite RI therapy [15, 17, 18] . The outcome of patients with bone metastasis has been reported to be poorer than the outcome of patients with lung metasreferences
